ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its anti-CD70 antibody IMM40H, following a previous US clinical nod. The drug is designed to target CD70, a protein found in highly activated lymphocytes and a viable target for hematological malignancies.
Drug Profile
- Mechanism: IMM40H has stronger CD70 affinity compared to Argenx’s Cusatuzumab, enabling more effective blocking of CD70-CD27 interaction.
- Efficacy: Preclinical studies show IMM40H exhibits strong ADCC, CDC, and ADCP activities, with significant anti-tumor efficacy in animal models.
- Safety: The drug demonstrated good safety in preclinical trials, with 2-3 treatments at lower doses capable of completely removing subcutaneous tumors.
Clinical Development
The NMPA approval allows ImmuneOnco to proceed with clinical trials in China, building on the US approval. The company plans to assess IMM40H’s potential in treating hematological malignancies.-Fineline Info & Tech
